NDC product
DANZITEN
NDC 24338-155 · Azurity Pharmaceuticals, Inc.
Key facts
| Product NDC | 24338-155 |
|---|---|
| Proprietary name | DANZITEN |
| Nonproprietary name | nilotinib |
| Substances | NILOTINIB |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Azurity Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA219293 |
| Pharmacologic classes | Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Kinase Inhibitor [EPC] and 2 more |
| Marketing start | Nov 30, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: